Vasily Andrianov

Statistics

Publications

Citations

H-Index

Active since

2023

Affiliations

Inhibrx (United States)(Current)

Ambrx (United States)

Vasily Andrianov is an author at Inhibrx (United States) specializing in pharmacodynamics of anticancer drugs, agonist activity, and durable clinical response.

ORCID

Publications per year

2023–2024

Publications

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Vivek Subbiah, Sant P. Chawla, Anthony P. Conley et al. · Clinical Cancer Research · 2023 · 42 citations · Full text

Medicine, Oncology, Pharmacology +13

Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study

Mark Brantly, Brooks Kuhn, Humam Farah et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2024 · 10 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +13

1–2 of 2